食管鳞状细胞癌管理的最新进展

Update on Management of Squamous Cell Esophageal Cancer.

作者信息

Waters John K, Reznik Scott I

机构信息

Division of Thoracic Surgery, Department of Cardiovascular and Thoracic Surgery, 5323 Harry Hines Boulevard, MC 8879, Dallas, TX, 75390-8879, USA.

出版信息

Curr Oncol Rep. 2022 Mar;24(3):375-385. doi: 10.1007/s11912-021-01153-4. Epub 2022 Feb 10.

Abstract

PURPOSE OF THE REVIEW

Esophageal cancer is the sixth most common cause of cancer death globally. Squamous cell carcinoma of the esophagus (ESCC) is the predominant histologic type in the world. Treatment strategies have evolved in the last decade and new paradigms are replacing traditional approaches at all stages of cancer. This review will summarize the epidemiology, diagnosis, staging, and treatment of esophageal squamous cell carcinoma.

RECENT FINDINGS

Novel approaches to screening may be cost-effective in regions with a high incidence of ESCC. Multi-disciplinary evaluation and treatment has become the standard of care. Endoscopic resection may be an option for early stage ESCC. Minimally invasive esophagectomy can be performed safely as a primary therapy or after-induction chemoradiation. Several recent studies have found a survival benefit to immunotherapy for patients with metastatic or persistent disease. Multi-disciplinary evaluation and multi-modal therapy including cytotoxic chemotherapy, radiation, surgery, and immunotherapy have improved survival compared to surgery alone.

摘要

综述目的

食管癌是全球第六大常见癌症死因。食管鳞状细胞癌(ESCC)是全球主要的组织学类型。过去十年中治疗策略不断发展,新的模式正在取代癌症各阶段的传统方法。本综述将总结食管鳞状细胞癌的流行病学、诊断、分期和治疗。

最新发现

在ESCC高发地区,新的筛查方法可能具有成本效益。多学科评估和治疗已成为标准治疗方式。内镜切除可能是早期ESCC的一种选择。微创食管切除术可作为主要治疗方法安全进行,也可在诱导放化疗后进行。最近的几项研究发现,免疫疗法对转移性或持续性疾病患者有生存益处。与单纯手术相比,包括细胞毒性化疗、放疗、手术和免疫疗法在内的多学科评估和多模式治疗提高了生存率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索